Inhibitory leukocyte immunoglobulin-like receptors in cancer development

FeiFei F. Zhang, JunKe K. Zheng, XunLei L. Kang, Mi Deng Ph.D., Zhigang Lu, Jaehyup Kim, Chengcheng Zhang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Inhibitory leukocyte immunoglobulin-like receptors (LILRB1-5) signal through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their intracellular domains and recruit phosphatases protein tyrosine phosphatase, non-receptor type 6 (PTPN6, SHP-1), protein tyrosine phosphatase, non-receptor type 6 (PTPN6, SHP-2), or Src homology 2 domain containing inositol phosphatase (SHIP) to negatively regulate immune cell activation. These receptors are known to play important regulatory roles in immune and neuronal functions. Recent studies demonstrated that several of these receptors are expressed by cancer cells. Importantly, they may directly regulate development, drug resistance, and relapse of cancer, and the activity of cancer stem cells. Although counterintuitive, these findings are consistent with the generally immune-suppressive and thus tumor-promoting roles of the inhibitory receptors in the immune system. This review focuses on the ligands, expression pattern, signaling, and function of LILRB family in the context of cancer development. Because inhibition of the signaling of certain LILRBs directly blocks cancer growth and stimulates immunity that may suppress tumorigenesis, but does not disturb normal development, LILRB signaling pathways may represent ideal targets for treating hematological malignancies and perhaps other tumors.

Original languageEnglish (US)
Pages (from-to)1216-1225
Number of pages10
JournalScience China Life Sciences
Volume58
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Non-Receptor Type 6 Protein Tyrosine Phosphatase
immunoglobulins
Immunoglobulins
cancer
leukocytes
Leukocytes
phosphatase
receptors
neoplasms
Tumors
protein-tyrosine-phosphatase
Neoplasms
tumor
Immune system
Phosphatases
Stem cells
Tyrosine
drug resistance
Chemical activation
Cells

Keywords

  • cancer
  • CD85
  • HLA
  • ILT
  • immunoglobulin-like transcript
  • immunoreceptor tyrosine-based activation motif
  • immunoreceptor tyrosine-based inhibitory motifs
  • ITAM
  • ITIM
  • leukemia
  • leukocyte immunoglobulin-like receptor
  • leukocyte immunoglobulin-like receptor subfamily B
  • LILRB
  • LIR
  • MHC
  • phosphatase
  • SHIP
  • SHP-1
  • SHP-2
  • signal transduction

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Environmental Science(all)

Cite this

Inhibitory leukocyte immunoglobulin-like receptors in cancer development. / Zhang, FeiFei F.; Zheng, JunKe K.; Kang, XunLei L.; Deng Ph.D., Mi; Lu, Zhigang; Kim, Jaehyup; Zhang, Chengcheng.

In: Science China Life Sciences, Vol. 58, No. 12, 01.12.2015, p. 1216-1225.

Research output: Contribution to journalArticle

Zhang, FeiFei F. ; Zheng, JunKe K. ; Kang, XunLei L. ; Deng Ph.D., Mi ; Lu, Zhigang ; Kim, Jaehyup ; Zhang, Chengcheng. / Inhibitory leukocyte immunoglobulin-like receptors in cancer development. In: Science China Life Sciences. 2015 ; Vol. 58, No. 12. pp. 1216-1225.
@article{b8bb8239483b4e76806c7de53e7fca3d,
title = "Inhibitory leukocyte immunoglobulin-like receptors in cancer development",
abstract = "Inhibitory leukocyte immunoglobulin-like receptors (LILRB1-5) signal through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their intracellular domains and recruit phosphatases protein tyrosine phosphatase, non-receptor type 6 (PTPN6, SHP-1), protein tyrosine phosphatase, non-receptor type 6 (PTPN6, SHP-2), or Src homology 2 domain containing inositol phosphatase (SHIP) to negatively regulate immune cell activation. These receptors are known to play important regulatory roles in immune and neuronal functions. Recent studies demonstrated that several of these receptors are expressed by cancer cells. Importantly, they may directly regulate development, drug resistance, and relapse of cancer, and the activity of cancer stem cells. Although counterintuitive, these findings are consistent with the generally immune-suppressive and thus tumor-promoting roles of the inhibitory receptors in the immune system. This review focuses on the ligands, expression pattern, signaling, and function of LILRB family in the context of cancer development. Because inhibition of the signaling of certain LILRBs directly blocks cancer growth and stimulates immunity that may suppress tumorigenesis, but does not disturb normal development, LILRB signaling pathways may represent ideal targets for treating hematological malignancies and perhaps other tumors.",
keywords = "cancer, CD85, HLA, ILT, immunoglobulin-like transcript, immunoreceptor tyrosine-based activation motif, immunoreceptor tyrosine-based inhibitory motifs, ITAM, ITIM, leukemia, leukocyte immunoglobulin-like receptor, leukocyte immunoglobulin-like receptor subfamily B, LILRB, LIR, MHC, phosphatase, SHIP, SHP-1, SHP-2, signal transduction",
author = "Zhang, {FeiFei F.} and Zheng, {JunKe K.} and Kang, {XunLei L.} and {Deng Ph.D.}, Mi and Zhigang Lu and Jaehyup Kim and Chengcheng Zhang",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s11427-015-4925-1",
language = "English (US)",
volume = "58",
pages = "1216--1225",
journal = "Science China. Life sciences",
issn = "1674-7305",
publisher = "Science in China Press",
number = "12",

}

TY - JOUR

T1 - Inhibitory leukocyte immunoglobulin-like receptors in cancer development

AU - Zhang, FeiFei F.

AU - Zheng, JunKe K.

AU - Kang, XunLei L.

AU - Deng Ph.D., Mi

AU - Lu, Zhigang

AU - Kim, Jaehyup

AU - Zhang, Chengcheng

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Inhibitory leukocyte immunoglobulin-like receptors (LILRB1-5) signal through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their intracellular domains and recruit phosphatases protein tyrosine phosphatase, non-receptor type 6 (PTPN6, SHP-1), protein tyrosine phosphatase, non-receptor type 6 (PTPN6, SHP-2), or Src homology 2 domain containing inositol phosphatase (SHIP) to negatively regulate immune cell activation. These receptors are known to play important regulatory roles in immune and neuronal functions. Recent studies demonstrated that several of these receptors are expressed by cancer cells. Importantly, they may directly regulate development, drug resistance, and relapse of cancer, and the activity of cancer stem cells. Although counterintuitive, these findings are consistent with the generally immune-suppressive and thus tumor-promoting roles of the inhibitory receptors in the immune system. This review focuses on the ligands, expression pattern, signaling, and function of LILRB family in the context of cancer development. Because inhibition of the signaling of certain LILRBs directly blocks cancer growth and stimulates immunity that may suppress tumorigenesis, but does not disturb normal development, LILRB signaling pathways may represent ideal targets for treating hematological malignancies and perhaps other tumors.

AB - Inhibitory leukocyte immunoglobulin-like receptors (LILRB1-5) signal through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their intracellular domains and recruit phosphatases protein tyrosine phosphatase, non-receptor type 6 (PTPN6, SHP-1), protein tyrosine phosphatase, non-receptor type 6 (PTPN6, SHP-2), or Src homology 2 domain containing inositol phosphatase (SHIP) to negatively regulate immune cell activation. These receptors are known to play important regulatory roles in immune and neuronal functions. Recent studies demonstrated that several of these receptors are expressed by cancer cells. Importantly, they may directly regulate development, drug resistance, and relapse of cancer, and the activity of cancer stem cells. Although counterintuitive, these findings are consistent with the generally immune-suppressive and thus tumor-promoting roles of the inhibitory receptors in the immune system. This review focuses on the ligands, expression pattern, signaling, and function of LILRB family in the context of cancer development. Because inhibition of the signaling of certain LILRBs directly blocks cancer growth and stimulates immunity that may suppress tumorigenesis, but does not disturb normal development, LILRB signaling pathways may represent ideal targets for treating hematological malignancies and perhaps other tumors.

KW - cancer

KW - CD85

KW - HLA

KW - ILT

KW - immunoglobulin-like transcript

KW - immunoreceptor tyrosine-based activation motif

KW - immunoreceptor tyrosine-based inhibitory motifs

KW - ITAM

KW - ITIM

KW - leukemia

KW - leukocyte immunoglobulin-like receptor

KW - leukocyte immunoglobulin-like receptor subfamily B

KW - LILRB

KW - LIR

KW - MHC

KW - phosphatase

KW - SHIP

KW - SHP-1

KW - SHP-2

KW - signal transduction

UR - http://www.scopus.com/inward/record.url?scp=84949321480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949321480&partnerID=8YFLogxK

U2 - 10.1007/s11427-015-4925-1

DO - 10.1007/s11427-015-4925-1

M3 - Article

C2 - 26566804

AN - SCOPUS:84949321480

VL - 58

SP - 1216

EP - 1225

JO - Science China. Life sciences

JF - Science China. Life sciences

SN - 1674-7305

IS - 12

ER -